Advanced search
Publication Cover
Cutaneous and Ocular Toxicology Volume 28, 2009 - Issue 1
Submit an article Journal homepage
146
Views
7
CrossRef citations to date
0
Altmetric
Case Study

Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer

Waris WarisNassau County University Hospital, East Meadow, New York, USA
,
Seeta NaikNassau County University Hospital, East Meadow, New York, USA
,
Imran IdreesNassau County University Hospital, East Meadow, New York, USA
,
Hesham TahaNassau County University Hospital, East Meadow, New York, USA
,
Linda CamosinoNassau County University Hospital, East Meadow, New York, USA
,
Anshu MehrishiNassau County University Hospital, East Meadow, New York, USA
&
Muhammad Wasif SaifYale University School of Medicine, New Haven, Connecticut, USACorrespondence[email protected]
 show all
Pages 41-44 | Received 25 Nov 2008, Published online: 01 Mar 2009

References

  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567–578.
  • Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235–5246.
  • Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803–812.
  • Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238–241.
  • Lacouture ME, Basti S, Patel J, Benson A. The SERIES clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors. J Support Oncol 2006; 4:236–238.
  • Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787–2799.
  • Gibson TB, Ranganatha A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29–31.
  • Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rishcin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110–124.
  • Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425–1433.
  • Sergi C, Kahl P, Otto HF. Immunohistochemical localization of transforming growth factor-α and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy. Pathol Oncol Res 2000; 6:250–255.
  • Pascual JC, Belinchon I, Sivera F, Yuste A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol 2005; 153:1222–1223.
  • Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997; 109:751–756.
  • Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelson DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803–1810.
  • Lièvre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold M-D, Rougier P, Ducreux M, Tomasic G, Emile J-F, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3):374–379.
  • Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169–1176.
  • Saltz L, Rubin MS, Hochster H, Tchekmeydian NS. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract 559]. Clin Cancer Res 2001; 7:3766s.
  • Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004; 29:138–140.
  • Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 2006; 20:5–13.
  • Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, Lo Russo P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.
  • Lenz HJ, Mayer RJ, Gold PJ. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract 3510]. J Clin Oncol 2004; 22:247s.
  • Verhagen AR. Pomade acne in black skin [letter]. Arch Dermatol 1974; 110(3):465.
  • Laude TA. Approach to dermatologic disorders in black children. Semin Dermatol 1995; 14(1):15–20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.